Article
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2014
Menzies Alexander M, Long Georgina V
Abstract excerpt
Dabrafenib and trametinib were approved for use as monotherapies in BRAF-mutant metastatic melanoma by the U.S. Food and Drug Administration (FDA) in 2013, and most recently, their use in combination has received accelerated FDA approval. Both drugs target the mitogen-activated protein kinase (MAPK) pathway: dabrafenib selectively inhibits mutant BRAF that constitutively activates the pathway, and trametinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.